275 related articles for article (PubMed ID: 25034978)
1. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
[TBL] [Abstract][Full Text] [Related]
7. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
O'Brien ME; Konopa K; Lorigan P; Bosquee L; Marshall E; Bustin F; Margerit S; Fink C; Stigt JA; Dingemans AM; Hasan B; Van Meerbeeck J; Baas P
Eur J Cancer; 2011 Oct; 47(15):2322-30. PubMed ID: 21684151
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
Inoue A; Ishimoto O; Fukumoto S; Usui K; Suzuki T; Yokouchi H; Maemondo M; Kanbe M; Ogura S; Harada T; Oizumi S; Harada M; Sugawara S; Fukuhara T; Nukiwa T
Ann Oncol; 2010 Apr; 21(4):800-803. PubMed ID: 19825887
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
10. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
Yilmaz U; Polat G; Anar C; Halilcolar H
Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
19. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
Spigel DR; Hainsworth JD; Shipley DL; Mekhail TM; Zubkus JD; Waterhouse DM; Daniel DB; Burris HA; Greco FA
Lung Cancer; 2018 Mar; 117():38-43. PubMed ID: 29496254
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
